Search

Your search keyword '"Lijnsvelt, Judith M"' showing total 3 results
Start Over Author "Lijnsvelt, Judith M"
3 results on '"Lijnsvelt, Judith M"'

1. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Author

Reijers, Irene L. M., Menzies, Alexander M., van Akkooi, Alexander C. J., Versluis, Judith M., van den Heuvel, Noëlle M. J., Saw, Robyn P. M., Pennington, Thomas E., Kapiteijn, Ellen, van der Veldt, Astrid A. M., Suijkerbuijk, Karijn P. M., Hospers, Geke A. P., Rozeman, Elisa A., Klop, Willem M. C., van Houdt, Winan J., Sikorska, Karolina, van der Hage, Jos A., Grünhagen, Dirk J., Wouters, Michel W., Witkamp, Arjen J., Zuur, Charlotte L., Lijnsvelt, Judith M., Torres Acosta, Alejandro, Grijpink-Ongering, Lindsay G., Gonzalez, Maria, Jóźwiak, Katarzyna, Bierman, Carolien, Shannon, Kerwin F., Ch’ng, Sydney, Colebatch, Andrew J., Spillane, Andrew J., Haanen, John B. A. G., Rawson, Robert V., van de Wiel, Bart A., van de Poll-Franse, Lonneke V., Scolyer, Richard A., Boekhout, Annelies H., Long, Georgina V., and Blank, Christian U.

Published
2022
Full Text
View/download PDF

2. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Author

MS Medische Oncologie, Infection & Immunity, Cancer, MS CGO, Reijers, Irene L M, Menzies, Alexander M, van Akkooi, Alexander C J, Versluis, Judith M, van den Heuvel, Noëlle M J, Saw, Robyn P M, Pennington, Thomas E, Kapiteijn, Ellen, van der Veldt, Astrid A M, Suijkerbuijk, Karijn P M, Hospers, Geke A P, Rozeman, Elisa A, Klop, Willem M C, van Houdt, Winan J, Sikorska, Karolina, van der Hage, Jos A, Grünhagen, Dirk J, Wouters, Michel W, Witkamp, Arjen J, Zuur, Charlotte L, Lijnsvelt, Judith M, Torres Acosta, Alejandro, Grijpink-Ongering, Lindsay G, Gonzalez, Maria, Jóźwiak, Katarzyna, Bierman, Carolien, Shannon, Kerwin F, Ch'ng, Sydney, Colebatch, Andrew J, Spillane, Andrew J, Haanen, John B A G, Rawson, Robert V, van de Wiel, Bart A, van de Poll-Franse, Lonneke V, Scolyer, Richard A, Boekhout, Annelies H, Long, Georgina V, Blank, Christian U, MS Medische Oncologie, Infection & Immunity, Cancer, MS CGO, Reijers, Irene L M, Menzies, Alexander M, van Akkooi, Alexander C J, Versluis, Judith M, van den Heuvel, Noëlle M J, Saw, Robyn P M, Pennington, Thomas E, Kapiteijn, Ellen, van der Veldt, Astrid A M, Suijkerbuijk, Karijn P M, Hospers, Geke A P, Rozeman, Elisa A, Klop, Willem M C, van Houdt, Winan J, Sikorska, Karolina, van der Hage, Jos A, Grünhagen, Dirk J, Wouters, Michel W, Witkamp, Arjen J, Zuur, Charlotte L, Lijnsvelt, Judith M, Torres Acosta, Alejandro, Grijpink-Ongering, Lindsay G, Gonzalez, Maria, Jóźwiak, Katarzyna, Bierman, Carolien, Shannon, Kerwin F, Ch'ng, Sydney, Colebatch, Andrew J, Spillane, Andrew J, Haanen, John B A G, Rawson, Robert V, van de Wiel, Bart A, van de Poll-Franse, Lonneke V, Scolyer, Richard A, Boekhout, Annelies H, Long, Georgina V, and Blank, Christian U

Published
2022

3. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Author

Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen JBAG, Ch'ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Grijpink-Ongering LG, van Akkooi ACJ, Reijers ILM, Gyorki DE, Grünhagen DJ, Speetjens FM, Vliek SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbé C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel FWPJ, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den Boer MAM, Atkinson V, Khattak M, Andrews MC, van den Eertwegh AJM, Boers-Sonderen MJ, Hospers GAP, Carlino MS, de Groot JB, Kapiteijn E, Suijkerbuijk KPM, Rutkowski P, Sandhu S, van der Veldt AAM, and Long GV

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Chemotherapy, Adjuvant methods, Chemotherapy, Adjuvant statistics & numerical data, Disease-Free Survival, Kaplan-Meier Estimate, Progression-Free Survival, Young Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Ipilimumab administration & dosage, Ipilimumab adverse effects, Ipilimumab therapeutic use, Melanoma mortality, Melanoma pathology, Melanoma therapy, Neoadjuvant Therapy methods, Neoadjuvant Therapy statistics & numerical data, Neoplasm Staging, Nivolumab therapeutic use, Nivolumab adverse effects, Nivolumab administration & dosage, Skin Neoplasms mortality, Skin Neoplasms pathology, Skin Neoplasms therapy
Abstract

Background: In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy., Methods: In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery or surgery followed by 12 cycles of adjuvant nivolumab. Only patients in the neoadjuvant group with a partial response or nonresponse received adjuvant treatment. The primary end point was event-free survival., Results: A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, the estimated 12-month event-free survival was 83.7% (99.9% confidence interval [CI], 73.8 to 94.8) in the neoadjuvant group and 57.2% (99.9% CI, 45.1 to 72.7) in the adjuvant group. The difference in restricted mean survival time was 8.00 months (99.9% CI, 4.94 to 11.05; P<0.001; hazard ratio for progression, recurrence, or death, 0.32; 99.9% CI, 0.15 to 0.66). In the neoadjuvant group, 59.0% of patients had a major pathological response, 8.0% had a partial response, 26.4% had a nonresponse (>50% residual viable tumor), and 2.4% had progression; in 4.2%, surgery had not yet been performed or was omitted. The estimated 12-month recurrence-free survival was 95.1% in patients in the neoadjuvant group who had a major pathological response, 76.1% among those with a partial response, and 57.0% among those with a nonresponse. Adverse events of grade 3 or higher that were related to systemic treatment occurred in 29.7% of patients in the neoadjuvant group and in 14.7% in the adjuvant group., Conclusions: Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, NCT04949113.)., (Copyright © 2024 Massachusetts Medical Society.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results